| [1] |
Huang DQ, Singal AG, Kanwal F, et al. Hepatocellular carcinoma surveillance-utilization, barriers and the impact of changing aetiology[J]. Nat Rev Gastroenterol Hepatol, 2023, 20:797-809.
|
| [2] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
|
| [3] |
Vogel A, Meyer T, Sapisochin G, et al. Hepatocellular carcinoma[J]. Lancet, 2022, 400(10360):1345-1362.
|
| [4] |
Toh MR, Wong EYT, Wong SH, et al. Global epidemiology and genetics of hepatocellular carcinoma[J]. Gastroenterology, 2023, 164(5):766-782.
|
| [5] |
Zeng H, Cao M, Xia C, et al. Performance and effectiveness of hepatocellular carcinoma screening in individuals with HBsAg seropositivity in China: a multicenter prospective study[J]. Nat Cancer, 2023, 4(9):1382-1394.
|
| [6] |
Wang YQ, Li HZ, Gong WW, et al. Cancer incidence and mortality in Zhejiang Province, Southeast China, 2016: a population-based study[J]. Chin Med J, 2021, 134(16):1959-1966.
|
| [7] |
Singal AG, Kudo M, Bruix J. Breakthroughs in hepatocellular carcinoma therapies[J]. Clin Gastroenterol Hepatol, 2023, 21(8):2135-2149.
|
| [8] |
Lee JE, Kim MY. Cancer epigenetics: past, present and future[J]. Semin Cancer Biol, 2022, 83:4-14.
|
| [9] |
Braghini MR, Re OL, Romito I, et al. Epigenetic remodelling in human hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2022, 41(1):107.
|
| [10] |
Ghiraldini FG, Filipescu D, Bernstein E. Solid tumours hijack the histone variant network[J]. Nat Rev Cancer, 2021, 21(4):257-275.
|
| [11] |
Hussain S, Tulsyan S, Dar SA, et al. Role of epigenetics in carcinogenesis: recent advancements in anticancer therapy[J]. Semin Cancer Biol, 2022, 83:441-451.
|
| [12] |
Guo L, Lee YT, Zhou Y, et al. Targeting epigenetic regulatory machinery to overcome cancer therapy resistance[J]. Semin Cancer Biol, 2022, 83:487-502.
|
| [13] |
Gomes AP, Ilter D, Low V, et al. Dynamic incorporation of histone H3 variants into chromatin is essential for acquisition of aggressive traits and metastatic colonization[J]. Cancer Cell, 2019, 36(4):402-417，e13.
|
| [14] |
Barbosa-Silva A, Magalhães M, Da Silva GF, et al. A data science approach for the identification of molecular signatures of aggressive cancers[J]. Cancers, 2022, 14(9):2325.
|
| [15] |
Yuan Y, Cao W, Zhou H, et al. H2A.Z acetylation by lincZNF337-AS1 via KAT5 implicated in the transcriptional misregulation in cancer signaling pathway in hepatocellular carcinoma[J]. Cell Death Dis, 2021, 12(6):609.
|
| [16] |
Yang B, Tong R, Liu H, et al. H2A.Z regulates tumorigenesis, metastasis and sensitivity to cisplatin in intrahepatic cholangiocarcinoma[J]. Int J Oncol, 2018, 52(4):1235-1245.
|
| [17] |
Tang S, Huang X, Wang X, et al. Vital and distinct roles of H2A.Z isoforms in hepatocellular carcinoma[J]. Onco Targets Ther, 2020, 13: 4319-4337.
|
| [18] |
Yang HD, Kim PJ, Eun JW, et al. Oncogenic potential of histone-variant H2A.Z.1 and its regulatory role in cell cycle and epithelial-mesenchymal transition in liver cancer[J]. Oncotarget, 2016, 7(10):11412-11423.
|
| [19] |
Martire S, Banaszynski LA. The roles of histone variants in fine-tuning chromatin organization and function[J]. Nat Rev Mol Cell Biol, 2020, 21(9):522-541.
|
| [20] |
Xie Y, Sahin M, Sinha S, et al. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes[J]. Nat Cancer, 2022, 3(2):188-202.
|
| [21] |
Latrick CM, Marek M, Ouararhni K, et al. Molecular basis and specificity of H2A.Z-H2B recognition and deposition by the histone chaperone YL1[J]. Nat Struct Mol Biol, 2016, 23(4):309-316.
|
| [22] |
Moreno-Andrés D, Yokoyama H, Scheufen A, et al. VPS72/YL1-mediated H2A.Z deposition is required for nuclear reassembly after mitosis[J]. Cells, 2020, 9(7):1702.
|
| [23] |
Liu F, Liao Z, Qin L, et al. Targeting VPS72 inhibits ACTL6A/MYC axis activity in HCC progression[J]. Hepatology, 2023, 78(5):1384-1401.
|